Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASH Highlights
Filter by Topic
ASH 2011 Annual Meeting
ASH 2013 Annual Meeting
ASH 2014 - Castleman's Disease
ASH 2014 - CLL
ASH 2015 - Multiple Myeloma
ASH 2015 – Castleman’s Disease, Lymphoma, and CLL
ASH 2015 – Leukemia
ASH 2017
ASH 2017 - Acute Myeloid Leukemia
ASH 2019 Wrap-up
Lisocabtagene Maraleucel, a CD19-Directed CAR T-Cell Product, in High-Risk Patients with R/R CLL/SLL, Including Those Previously Treated with Ibrutinib
ASH 2019 Wrap-up
,
ASH Highlights
Conference Correspondent
Results from TRANSCEND CLL 004 showed chimeric antigen receptor (CAR) T-cell treatment with lisocabtagene maraleucel in heavily pretreated patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who had failed ibrutinib was manageable and produced durable undetectable minimal residual disease responses.
Read Article
Three-Year Update of the Phase 2 ABT-199 (Venetoclax) and Ibrutinib in Mantle-Cell Lymphoma (AIM) Study
ASH 2019 Wrap-up
,
ASH Highlights
Conference Correspondent
Results from the 3-year update of the phase 2 AIM trial confirmed the effectiveness of ibrutinib + venetoclax therapy for patients with mantle-cell lymphoma, and indicated that treatment interruption was feasible for patients in minimal residual disease–negative complete remissions.
Read Article
Bendamustine-Rituximab versus Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma
ASH 2019 Wrap-up
,
ASH Highlights
Conference Correspondent
A large observational study showed increased first-line bendamustine-rituximab use among older patients with splenic or nodal marginal zone lymphoma was not associated with significant event-free survival or overall survival benefit versus single-agent rituximab, but led to increased toxicities and costs.
Read Article
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory CLL: 42-Month Follow-Up of a Phase 2 Study
ASH 2019 Wrap-up
,
ASH Highlights
Conference Correspondent
Updated results from a phase 1/2 trial indicate that acalabrutinib monotherapy was associated with a favorable safety profile and showed antileukemic activity in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma, irrespective of high-risk genomic features.
Read Article
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
ASH 2017
,
Multiple Myeloma
,
Palliative Care
,
Hematologic Malignancies
,
ASH Highlights
Web Exclusives
Read Article
Encouraging Efficacy and Safety with Enasidenib or Ivosidenib plus Azacitidine in Patients with Newly Diagnosed AML
ASH 2017
,
ASH Highlights
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Enasidenib and ivosidenib monotherapy have demonstrated induction of clinical responses in patients with mutant
IDH
(m
IDH
) relapsed/refractory acute myeloid leukemia (AML), whereas azacitidine (AZA) monotherapy prolongs survival in older patients with the newly diagnosed (ND) AML. Based on these results and coupled with preclinical evidence of synergy with combination of m
IDH
inhibitors plus AZA, an ongoing phase 1b/2 study evaluated the efficacy and safety of this combination in ND AML; results of the phase 1b portion were reported at ASH 2017.
Read Article
Safety and Tolerability of Midostaurin from Expanded Treatment Protocol in Patients with FLT3 Mutation–Positive, Newly Diagnosed AML
ASH 2017
,
ASH Highlights
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Midostaurin, a multikinase inhibitor targeting
FLT3
and
KIT
, is indicated for the treatment of patients with newly diagnosed,
FLT3
mutation–positive acute myeloid leukemia (AML) in combination with standard induction and consolidation chemotherapy, based on demonstrations of superior survival outcomes versus placebo in the randomized, double-blind, phase 3 RATIFY trial. The Radius-X open-label expanded treatment protocol (ETP) was designed to provide access to midostaurin and obtain additional insights into the safety and tolerability profile of midostaurin in adult patients with newly diagnosed,
FLT3
mutation–positive AML.
Read Article
Enasidenib Monotherapy Is Well-Tolerated and Active in Older Patients with Untreated mIDH2 AML
ASH 2017
,
ASH Highlights
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Enasidenib (AG-221) is a novel, small-molecule oral inhibitor of mutated
IDH2
(m
IDH2
) proteins that is currently indicated for the treatment of adult patients with m
IDH
-positive relapsed or refractory (R/R) acute myeloid leukemia (AML). The phase 1 AG221-C-001 study demonstrated the clinical efficacy of enasidenib in patients with m
IDH2
R/R AML. Given the limited treatment options for older patients with untreated AML, the current analysis sought to evaluate the clinical outcomes for older patients with previously untreated m
IDH2
AML who received enasidenib monotherapy in the AG221-C-001 study.
Read Article
Nivolumab plus Azacitidine Shows Encouraging Activity in R/R AML or as Frontline Therapy in Elderly Patients with AML
ASH 2017
,
ASH Highlights
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Available preclinical and clinical evidence suggests that inhibition of PD-1/PD-L1 pathways increases antileukemic responses in acute myeloid leukemia (AML). Moreover, azacitidine treatment results in upregulation of PD-1 signaling, which is associated with azacitidine resistance. Based on this rationale, the current study evaluated the safety and efficacy of combination nivolumab plus azacitidine treatment in 2 patient cohorts: those with relapsed or refractory (R/R) AML with poor-risk features, and in elderly patients with untreated AML.
Read Article
Lenalidomide plus Elotuzumab Maintenance Regimen Improves Responses in Multiple Myeloma
By
Wayne Kuznar
ASH 2017
,
Multiple Myeloma
,
Hematologic Malignancies
,
ASH Highlights
February 2018, Vol 9, No 1 | Payers' Perspectives In Oncology: ASH 2017 Highlights
Atlanta, GA—A maintenance regimen of lenalidomide (Revlimid) and elotuzumab (Empliciti) after autologous stem-cell transplant (ASCT) improved the quality of responses achieved with induction therapy in patients with multiple myeloma.
Read Article
Page 2 of 15
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma